OraPharma believes oral health is a vital component of overall health. Our goal is to exceed customers' expectations by providing exceptional products and solutions that improve their dental practices and patient care, making OraPharma the oral health partner of choice for customers globally.
In 1996, OraPharma was founded as a specialty pharmaceutical company dedicated to oral healthcare. Our flagship product, ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg, was approved by the FDA in 2001 and advanced the treatment of periodontal disease. From 2002 to 2010, OraPharma operated as a subsidiary of Johnson & Johnson.
In 2012, OraPharma was acquired by Valeant Pharmaceuticals International, Inc., from a strategic private equity firm. Valeant is a multi-national specialty pharmaceutical company with a diverse product portfolio focused on branded pharmaceuticals, branded generics, and over-the-counter (OTC) products. More than ever, Valeant is committed to building OraPharma into a leader in oral healthcare.